Pegylated Liposomal Doxorubicin Hydrochloride and Bevacizumab in Treating Patients with Advanced Kaposi Sarcoma

Inclusion Criteria

• Kaposi’s sarcoma pathologically confirmed by Center for Cancer Research (CCR) pathology
• Evaluable KS involving the skin and/or viscera, including at least one of the following: * KS of the skin with >= 5 KS lesions that are evaluable by non-invasive methods that have not been treated with local therapeutic modalities * Pulmonary KS evaluable by computed tomography (CT) scan * Gastrointestinal KS evaluable by direct visualization or fiberoptic instrumentation * Biopsy proven lymph node involvement measurable by CT scan
• Eastern Cooperative Oncology Group (ECOG) performance status =< 2
• Life expectancy > 6 months
• At least one of the following indications for therapy: * Pulmonary involvement * Visceral involvement * Pain * Edema * Substantial lymph node involvement * Ulcerating lesions * Decreased range of joint motion due to KS * Multiple lesions not amenable to local therapy * Significant psychological impact leading to social withdrawal
• Patients with human immunodeficiency virus (HIV) infection must be willing to comply with a regimen of highly active antiretroviral therapy (HAART)
• Patients may have received any number of prior therapies, including monotherapy with liposomal doxorubicin or bevacizumab
• Blood pressure * Systolic blood pressure (SBP) < 150 mm/Hg * Diastolic blood pressure (DBP) < 90 mm/Hg
• Patients receiving anti-hypertensive medicines must be on a stable regimen for at least 1 month
• Ejection fraction (EF) > 50% by multi gated acquisition scan (MUGA)
• Hemoglobin > 9 g/dl
• White blood cell (WBC) > 1000/mm^3
• Absolute neutrophil count (ANC) > 750/mm^3
• Platelets > 75,000/mm^3
• Prothrombin time (PT) and partial thromboplastin time (PTT) =< 120% of control, unless patient has the presence of a lupus anticoagulant
• Bilirubin =< 1.5 X upper limit of normal (ULN) unless the patient is receiving protease inhibitor therapy (i.e. indinavir, ritonavir, nelfinavir, and atazanavir) known to be associated with increased bilirubin: in this case total bilirubin =< 7.5 mg/dl and the direct fraction is =< 0.7 mg/dl
• Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) =< 2.5 times the upper limit of normal
• Either serum creatinine =< 1.5 mg/dL or measured creatinine clearance >= 60 mL/min
• Either urine protein < 1+ or measured 24 hour urine protein < 500 milligram
• Able to take aspirin 81 mg daily
• Study participant must use birth control measure prior to study entry (during screening), during study participation, and for 12 weeks after bevacizumab is discontinued
• Inclusion of women and minorities: both men and women and members of all races and ethnic groups are eligible for this trial

Exclusion Criteria

• Inability to provide informed consent
• KS therapy other than HAART within 3 weeks
• History of cumulative doxorubicin or liposomal doxorubicin dose > 430 mg/m^2
• Supraphysiologic doses of corticosteroids within 3 weeks
• Major surgical procedure (including periodontal) within 4 weeks
• Surgical or other non-healing wounds, other than KS ulcers
• Pregnancy
• Breast feeding
• Has an uncontrolled illness including, but not limited to, ongoing or active infection requiring IV antibiotics, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, cirrhosis, or psychiatric illness/social situations that would limit adherence to study requirements
• Past or present history of malignant tumors other than KS unless: a) in a complete remission for >= 1 year from the time a response was first documented; b) completely resected basal cell carcinoma; or c) in situ squamous cell carcinoma of the cervix or anus
• Severe or life-threatening infection within 2 weeks of entry onto the study
• History of deep venous or arterial thrombotic disease (including but not limited to, acute myocardial infarction due to coronary thrombosis, ischemic stroke, and peripheral arterial disease), unless: * Line-related thrombosis without embolus * Occurring >= 1 year prior to screening
• Known procoagulant disorder including prothrombin gene mutation 20210, antithrombin III deficiency, protein C deficiency, protein S deficiency and antiphospholipid syndrome but not including heterozygosity for the Factor V Leiden mutation or the presence of a lupus anticoagulant in the absence of other criteria for the antiphospholipid syndrome
• Known bleeding diathesis
• History of severe gastrointestinal bleeding within 6 months; patients with gastrointestinal blood loss due to KS may be included
• Hemoptysis within 4 weeks
• Substantial central nervous system (CNS) disease including * History of CNS bleeding * Mass lesions in the brain * Uncontrolled seizure disorder * Recent history of cerebrovascular accident (CVA) (e.g. within the past 6 months)
• Proteinuria > 500 mg/24hrs
• Patients with any other abnormality that would be scored as a grade 3 or greater toxicity, except: * Lymphopenia * Direct manifestations of KS * Direct manifestation of HIV * Direct manifestation of HIV therapy (i.e. hyperbilirubinemia associated with protease inhibitors) * Asymptomatic hyperuricemia * Hypophosphatemia
• Previous bevacizumab within 6 weeks prior to enrollment
• Known hypersensitivity to bevacizumab, Chinese hamster ovary cell products, or other recombinant human or humanized antibodies
• Any condition, including the presence of laboratory abnormalities, which in the opinion of the principal investigator or lead associate investigator places the subject at unacceptable risk if they were to participate in the study or confounds the ability to interpret data from the study